RimabotulinumtoxinB (Myobloc)

Myobloc (rimabotulinumtoxinB) is covered only for the FDA‑approved use—treatment of adult cervical dystonia—and non‑FDA indications are excluded. Coverage requires the patient be ≥18 years old with documented failure of or tolerance to onabotulinumtoxinA (Botox); authorization is for up to 12 months, maximum 5000 units per treatment given intramuscularly no more frequently than every 12 weeks.

"Myobloc (rimabotulinumtoxinB) is indicated for the treatment of adults with cervical dystonia."

Sign up to see full coverage criteria, indications, and limitations.